June 22, 2020

New Data Show Theratechnologies’ SORT1+ Technology Is Effective In Many Treatment-Resistant Cancers

Peptide-drug conjugates TH1902 and TH1904 show significant reduction in the formation of vasculogenic mimicry by targeting the sortilin receptor

 Curcumin shows increased anticancer activity when conjugated to proprietary peptide

 SORT1+ technology significantly widens therapeutic window
of traditional cytotoxic cancer treatments

 Montreal, Canada – June 22, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American Association for Cancer Research’s virtual annual meeting II.

“We believe that our SORT1+ technology is one of the most promising advances in the treatment of cancer in many years. As our oncology programs progress through clinical development, we hope to continue to demonstrate that our SORT1+ technology could become a new paradigm in cancer treatment,” said Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, Theratechnologies.